EQT agreed to acquire Qiagen for €10.8 billion (about $12.1 billion) in an all-cash transaction, taking the life-sciences tools and diagnostics provider private. The move follows a multi-year takeover landscape and comes after Qiagen’s boards completed a strategic review and concluded private ownership would offer greater flexibility. Qiagen said the acquisition provides shareholders certain value and supports a longer-term development plan under EQT’s ownership. Financial details include net debt considerations and a premium referenced against recent share prices, with shareholder support required for completion. For the biotech ecosystem, a buyout of a scale operator in sample-to-insight workflows can reshape pricing, product roadmaps and availability of instruments and consumables used across translational and clinical labs.